Medicare & Medicaid
News articles in this section include actions by federal regulators like the CMS and HHS, as well as information on Medicare and state Medicaid coverage and benefits.
Between 2011 and 2017, Medicare could have saved $17.7 billion if generic versions of older medicines were prescribed instead of updated brand-name drugs launched by drugmakers to replace their older off-patent pills, according to a new study published in the Annals of Internal Medicine.
Fewer large, self-insured employers will offer a high-deductible health plan as the only employee insurance option next year, opting instead to give employees more choice when it comes to health coverage.
The American Medical Association (AMA), the nation’s main group for doctors, announced Thursday that it is leaving a coalition fighting "Medicare for All," a blow to the industry’s efforts to push back on the progressive proposal.
A top Trump health administrator on Thursday said that officials are actively “working on” a plan to repeal and replace ObamaCare, which has remained a priority for President Trump even as many congressional Republicans look to move on.
If health insurers have their way, Medicare for All will be a nonstarter. And they’ve got the lobbying battle lines drawn to prove it—with pharmaceutical companies on their side.
Though support or opposition for “Medicare for All” is dominating the 2020 primary headlines, a large group of Americans is more ambivalent about the proposal, a new survey shows.
Medicare-for-All proposals have sparked discussion about the role of private health insurance in the U.S. health care system. Some of the current Medicare-for-All proposals would essentially eliminate private insurance.
Health insurance enrollment declined among people who do not qualify for financial help under ObamaCare as premiums rose to make coverage less affordable, new federal data shows.
Taxes are playing a leading role in the health care debate that’s dividing the field of 2020 Democratic presidential candidates. Centrist candidates are criticizing their opponents on the left who support the single-payer proposal known as “Medicare for All” by arguing that it is too expensive and would require tax hikes for the middle class.
Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc and Novartis AG.